The Susan G. Komen for the Cure foundation has long positioned itself as the leading voice in the fight against breast cancer. Through its iconic pink ribbon campaigns and “Race for the Cure” events, the organization raises tens of millions of dollars annually. However, a growing number of medical professionals and researchers have raised pointed questions about how those funds are deployed and whether the organization’s messaging accurately reflects the science of breast cancer screening.

The BMJ Study That Challenged Komen’s Claims

In a peer-reviewed article published in the British Medical Journal, researchers Steven Woloshin and Lisa Schwartz of Dartmouth Medical School’s Center for Medicine and the Media accused Komen of using misleading statistics in its promotional materials. Specifically, they challenged a 2011 Breast Cancer Awareness Month advertisement that claimed a 98 percent five-year survival rate when cancer is caught early, compared to just 23 percent when it is not.

According to Woloshin and Schwartz, these figures misrepresent the actual impact of screening. The real 10-year risk of a 50-year-old woman dying from breast cancer sits at approximately 0.53 percent. With mammography screening, that number shifts to roughly 0.46 percent, a reduction of just 0.07 percent, or seven women per 10,000.

The False Alarm Problem

Beyond the question of marginal benefit, the researchers highlighted significant harms associated with routine mammography screening. Between 20 and 50 percent of women who undergo annual mammograms over a decade will experience at least one false positive result requiring a biopsy.

These false alarms can trigger cascades of unnecessary treatment, including chemotherapy and radiation, exposing patients to serious side effects without corresponding medical benefit. The researchers noted that for every life saved by mammography, an estimated two to ten women are overdiagnosed, meaning their detected cancers would never have caused symptoms or death.

Corporate Partnerships and Financial Entanglements

Questions about Komen’s objectivity intensified when observers noted the organization’s financial ties to companies that profit from mammography and cancer treatment. The foundation reportedly held stock in General Electric, one of the world’s largest manufacturers of mammogram machines, as well as positions in pharmaceutical companies including AstraZeneca.

DuPont, which supplies film used in mammography equipment, and Monsanto, a sponsor of Race for the Cure events, were also connected to the organization. Komen’s corporate partner roster included General Mills, Walgreens, Bank of America, Ford Motor Company, and numerous other major brands.

Where the Money Actually Goes

Financial disclosures revealed that Susan G. Komen for the Cure held assets exceeding $390 million, yet only approximately 20.9 percent of funds were directed toward research during the 2009-2010 fiscal year. Roughly 39 percent of spending went toward what the organization classified as “public health education,” which critics characterized as marketing designed to sustain future fundraising.

Executive compensation also drew scrutiny. The organization’s CEO and president reportedly earned over $530,000 annually, a figure that exceeded the salary of the sitting U.S. president at the time.

Targeting Vulnerable Communities

Komen’s mobile mammography programs were concentrated in low-income and predominantly Black neighborhoods in cities like Detroit, where breast cancer rates among African American women already ran significantly higher than in other demographics. Critics argued that this approach, combined with the documented risks of mammography-induced radiation exposure, raised serious ethical questions about whether these outreach efforts genuinely served the communities they claimed to help.

The Broader Debate Over Screening

The controversy surrounding Komen reflected a wider medical debate about the value of routine mammography screening. The National Breast Cancer Coalition, a major U.S. network of patient and professional organizations, stated that there was “insufficient evidence to recommend for or against universal mammography in any age group of women.”

Woloshin and Schwartz found that even many primary care physicians misunderstood screening statistics. In a survey conducted with colleagues from the Max Planck Institute, most U.S. primary care doctors incorrectly interpreted improved survival rates as evidence that screening saves lives, a statistical error that the researchers attributed in part to misleading messaging from organizations like Komen.

The Case for Prevention Over Detection

Medical researchers have increasingly emphasized that detection and prevention are fundamentally different strategies. While mammography identifies existing tumors, it does nothing to reduce the likelihood of cancer developing in the first place. Emerging research during this period highlighted the role of vitamin D levels in breast cancer risk reduction, a topic that organizations focused on screening-based approaches largely overlooked.

The debate raised broader questions about whether the dominant narrative around breast cancer, one centered on early detection through screening, had crowded out equally important conversations about environmental carcinogens, lifestyle factors, and preventive health measures that could reduce cancer incidence rather than simply identifying it after the fact.